X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8554) 8554
Publication (668) 668
Book Review (214) 214
Newsletter (48) 48
Book Chapter (24) 24
Magazine Article (12) 12
Conference Proceeding (10) 10
Newspaper Article (6) 6
Dissertation (3) 3
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
infliximab (7567) 7567
humans (7017) 7017
index medicus (4498) 4498
female (4037) 4037
male (3873) 3873
adult (3130) 3130
middle aged (2946) 2946
tumor necrosis factor-alpha - antagonists & inhibitors (2774) 2774
antibodies, monoclonal - therapeutic use (2761) 2761
antibodies, monoclonal - adverse effects (2678) 2678
treatment outcome (2309) 2309
etanercept (2225) 2225
adalimumab (2050) 2050
gastroenterology & hepatology (1919) 1919
rheumatology (1878) 1878
therapy (1690) 1690
aged (1546) 1546
arthritis, rheumatoid - drug therapy (1482) 1482
rheumatoid-arthritis (1407) 1407
crohn disease - drug therapy (1372) 1372
antirheumatic agents - adverse effects (1352) 1352
antirheumatic agents - therapeutic use (1330) 1330
rheumatoid arthritis (1323) 1323
crohns-disease (1256) 1256
crohn's disease (1178) 1178
inflammatory-bowel-disease (1120) 1120
efficacy (1044) 1044
inflammatory bowel disease (1013) 1013
double-blind (1010) 1010
retrospective studies (981) 981
methotrexate (980) 980
adolescent (975) 975
care and treatment (944) 944
dermatology (941) 941
drug therapy (937) 937
safety (891) 891
monoclonal antibodies (889) 889
ulcerative colitis (882) 882
psoriasis (866) 866
pharmacology & pharmacy (843) 843
young adult (829) 829
antibodies, monoclonal - administration & dosage (816) 816
risk factors (809) 809
immunosuppressive agents - therapeutic use (801) 801
arthritis (761) 761
immunoglobulin g - therapeutic use (760) 760
severity of illness index (753) 753
receptors, tumor necrosis factor - therapeutic use (751) 751
anti-inflammatory agents - therapeutic use (740) 740
drug therapy, combination (708) 708
medicine & public health (705) 705
necrosis-factor-alpha (703) 703
patients (700) 700
antibodies, monoclonal, humanized (669) 669
immunoglobulin g - adverse effects (668) 668
tumor necrosis factor (652) 652
colitis, ulcerative - drug therapy (632) 632
tumor necrosis factor-tnf (625) 625
anti-inflammatory agents - adverse effects (624) 624
follow-up studies (616) 616
tumor necrosis factor-α (613) 613
psoriasis - drug therapy (610) 610
infliximab - therapeutic use (605) 605
immunosuppressive agents - adverse effects (598) 598
gastrointestinal agents - therapeutic use (597) 597
child (588) 588
inflammatory bowel diseases - drug therapy (583) 583
gastrointestinal agents - adverse effects (574) 574
time factors (570) 570
immunology (564) 564
disease (548) 548
tumor-necrosis-factor (547) 547
antibodies, monoclonal, humanized - therapeutic use (514) 514
risk (514) 514
abridged index medicus (513) 513
medicine, general & internal (501) 501
ulcerative-colitis (488) 488
infliximab - adverse effects (483) 483
prospective studies (481) 481
tumor necrosis factor-alpha - immunology (474) 474
research (473) 473
monoclonal-antibody (471) 471
health aspects (470) 470
remission (464) 464
remission induction (460) 460
analysis (454) 454
management (442) 442
azathioprine (436) 436
methotrexate - therapeutic use (428) 428
internal medicine (418) 418
trial (417) 417
dosage and administration (403) 403
tnf-alpha (402) 402
clinical trials (400) 400
tuberculosis (397) 397
maintenance therapy (391) 391
animals (389) 389
surgery (389) 389
antibodies, monoclonal, humanized - adverse effects (378) 378
drug administration schedule (375) 375
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8167) 8167
Spanish (113) 113
French (104) 104
German (102) 102
Japanese (79) 79
Italian (19) 19
Danish (17) 17
Russian (16) 16
Portuguese (15) 15
Chinese (11) 11
Korean (11) 11
Dutch (8) 8
Hungarian (6) 6
Swedish (6) 6
Turkish (5) 5
Czech (4) 4
Norwegian (4) 4
Polish (4) 4
Croatian (2) 2
Finnish (2) 2
Hebrew (2) 2
Lithuanian (1) 1
Romanian (1) 1
Serbian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cytokine, ISSN 1043-4666, 01/2018, Volume 101, pp. 56 - 63
Tumor necrosis factor (TNF)-α is a potent pro-inflammatory and pathological cytokines in inflammatory diseases such as rheumatoid arthritis and inflammatory... 
Anti-TNF-α therapy | Inflammatory bowel disease | Tumor necrosis factor-α | Rheumatoid arthritis | RHEUMATOID-ARTHRITIS | COLLAGEN-INDUCED ARTHRITIS | CROHNS-DISEASE | BIOCHEMISTRY & MOLECULAR BIOLOGY | Anti-TNF-alpha therapy | IMMUNOLOGY | FC-FUSION PROTEINS | CERTOLIZUMAB PEGOL | FACTOR RECEPTOR | CELL BIOLOGY | Tumor necrosis factor-alpha | TUMOR-NECROSIS-FACTOR | INFLAMMATORY-BOWEL-DISEASE | TRANSMEMBRANE TNF | REGULATORY T-CELLS | Adalimumab - genetics | Antirheumatic Agents - administration & dosage | Humans | Immunoglobulin Fab Fragments - adverse effects | Immunosuppressive Agents - therapeutic use | Inflammatory Bowel Diseases - immunology | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Immunoglobulin Fab Fragments - therapeutic use | Infliximab - therapeutic use | Polyethylene Glycols - therapeutic use | Antibodies, Monoclonal, Humanized - genetics | Adalimumab - adverse effects | Certolizumab Pegol - adverse effects | Infliximab - adverse effects | Anti-Inflammatory Agents - adverse effects | Antibodies, Monoclonal, Humanized - administration & dosage | Arthritis, Rheumatoid - drug therapy | Tumor Necrosis Factor-alpha - immunology | Anti-Inflammatory Agents - therapeutic use | Antirheumatic Agents - adverse effects | Anti-Inflammatory Agents - administration & dosage | Certolizumab Pegol - therapeutic use | Certolizumab Pegol - genetics | Immunosuppressive Agents - administration & dosage | Antirheumatic Agents - therapeutic use | Disease Models, Animal | Inflammatory Bowel Diseases - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | Etanercept - adverse effects | Infliximab - genetics | Antibodies, Monoclonal, Humanized - therapeutic use | Immunoglobulin Fab Fragments - genetics | Immunoglobulin G - therapeutic use | Immunologic Factors - genetics | Immunoglobulin G - adverse effects | Antibodies, Monoclonal - genetics | Adalimumab - therapeutic use | Animals | Immunoglobulin G - genetics | Immunosuppressive Agents - adverse effects | Immunologic Factors - adverse effects | Mice | Arthritis, Rheumatoid - immunology | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Etanercept - therapeutic use | Immunologic Factors - therapeutic use
Journal Article
American Journal of Gastroenterology, ISSN 0002-9270, 01/2013, Volume 108, Issue 1, pp. 99 - 105
OBJECTIVES: The risk of non-Hodgkin's lymphoma (NHL) with tumor necrosis factor alpha (TNF-alpha) inhibitors is unclear, whether related to concomitant... 
RHEUMATOID-ARTHRITIS | INFLAMMATORY-BOWEL-DISEASE | THERAPY | AZATHIOPRINE | RISK | INFLIXIMAB | GASTROENTEROLOGY & HEPATOLOGY | CANCER | MEDLINE | Azathioprine - therapeutic use | Lymphoma, T-Cell - chemically induced | Certolizumab Pegol | United States | Humans | Immunoglobulin Fab Fragments - adverse effects | Immunosuppressive Agents - therapeutic use | Middle Aged | Antibodies, Monoclonal - adverse effects | Polyethylene Glycols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Immunoglobulin Fab Fragments - therapeutic use | Polyethylene Glycols - therapeutic use | Receptors, Tumor Necrosis Factor - therapeutic use | Etanercept | Infliximab | Arthritis, Rheumatoid - drug therapy | Mercaptopurine - therapeutic use | Aged, 80 and over | Adult | Female | Drug Therapy, Combination | Odds Ratio | United States Food and Drug Administration | Inflammatory Bowel Diseases - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | SEER Program | Antibodies, Monoclonal, Humanized - therapeutic use | Psoriasis - drug therapy | Adverse Drug Reaction Reporting Systems | Risk Factors | Spondylitis, Ankylosing - drug therapy | Mercaptopurine - adverse effects | Immunoglobulin G - therapeutic use | Immunoglobulin G - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Immunosuppressive Agents - adverse effects | Aged | Adalimumab | Azathioprine - adverse effects | Tumor Necrosis Factor-alpha - antagonists & inhibitors
Journal Article
Gastroenterology, ISSN 0016-5085, 2016, Volume 150, Issue 2, pp. 380 - 388.e4
Journal Article
Archives of Dermatological Research, ISSN 0340-3696, 1/2009, Volume 301, Issue 1, pp. 99 - 105
Drug-induced lupus erythematosus (DILE) is defined as a lupus-like syndrome temporally related to continuous drug exposure which resolves after discontinuation... 
Drug-induced lupus erythematosus | Antinuclear antibodies (ANA) | Medicine & Public Health | Dermatology | Anti-TNFα-induced lupus | Anti-histone antibodies | Subacute cutaneous drug-induced lupus (SCLE) | Drug reactions | RHEUMATOID-ARTHRITIS | AUTOANTIBODIES | ANTINUCLEAR | NECROSIS-FACTOR-ALPHA | INDUCTION | DERMATOLOGY | Anti-TNF alpha-induced lupus | THERAPY | INFLIXIMAB | ASSOCIATION | EPIDEMIOLOGY | PSORIASIS | Antifungal Agents - adverse effects | Antitubercular Agents - adverse effects | Naphthalenes - adverse effects | Antibodies - metabolism | Calcium Channel Blockers - adverse effects | Serositis | Exanthema | Humans | Isoniazid - adverse effects | Interferons - adverse effects | Antihypertensive Agents - administration & dosage | Sodium Chloride Symporter Inhibitors - adverse effects | Arthritis | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Lupus Erythematosus, Systemic - immunology | Sodium Chloride Symporter Inhibitors - administration & dosage | Tumor Necrosis Factor-alpha - immunology | Antibodies - immunology | Lupus Erythematosus, Cutaneous - chemically induced | Procainamide - administration & dosage | Lupus Erythematosus, Cutaneous - immunology | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Anti-Arrhythmia Agents - administration & dosage | Procainamide - adverse effects | Antihypertensive Agents - adverse effects | Hydralazine - adverse effects | Isoniazid - administration & dosage | Lupus Erythematosus, Systemic - diagnosis | Interferons - administration & dosage | Hydralazine - administration & dosage | Animals | Anti-Arrhythmia Agents - adverse effects | Naphthalenes - administration & dosage | Calcium Channel Blockers - administration & dosage | Antitubercular Agents - administration & dosage | Lupus Erythematosus, Systemic - chemically induced | Antifungal Agents - administration & dosage | Lupus Erythematosus, Cutaneous - diagnosis | Lupus | Antigen-antibody reactions | Enzymes | Antigens | Biological products | Antibodies | Viral antibodies | Enzyme inhibitors | Systemic lupus erythematosus | Fluocinolone acetonide | Calcium channel blockers | Diuretics | Kidney diseases | Hydralazine | Index Medicus
Journal Article
JEADV : Journal of the European Academy of Dermatology and Venereology, ISSN 0926-9959, 2009, Volume 23 Suppl 2, Issue 2, pp. 1 - 70
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2013, Volume 70, Issue 1, pp. 168 - 177
Journal Article
Journal of the European Academy of Dermatology and Venereology, ISSN 0926-9959, 01/2015, Volume 29, Issue 1, pp. 156 - 163
Journal Article